. Author manuscript; available in PMC: 2024 Apr 1.

Published in final edited form as: J Am Acad Dermatol. 2023 Jan 20;88(4):841–847. doi: 10.1016/j.jaad.2023.01.014

Table 4 –

One-year incidence of inflammatory bowel among patients with acne treated with isotretinoin in comparison to patients with acne treated without oral tetracycline class antibiotics, spironolactone, or isotretinoin

	Acne			Isotretinoin			Odds Ratio	95% CI
	Patients, total, n	Patients with incident outcome, n	IR/1000	Patients, total, n	Patients with incident outcome, n	IR/1000	Odds Ratio	95% CI
Outcomes
Any inflammatory bowel disease	11,194	14	1.25	11,199	18	1.61	1.29	0.64–2.59
Crohn’s disease	11,241	12	1.07	11,231	12	1.07	1.00	0.45–2.23
Ulcerative colitis	11,247	11	0.98	11,255	14	1.24	1.27	0.58–2.80